Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...
In parallel, Gilead is also planning to carry out a study of lenacapavir for HIV prevention in men and transgender people who have sex with men. PrEP is already a big market for HIV drugs like its ...
世界卫生组织(WHO)近期在官网上宣布,正在召集一个专门的指南制定小组(GDG),以更新艾滋病暴露前预防(PrEP)的使用指南,尤其是针对注射用药物来那卡帕韦(lenacapavir)的使用。这一更新显示出WHO对当前公共卫生需求的高度关注,特别是针对受到艾滋病毒影响严重的群体,确保他们能获得高质量的艾滋预防和检测服务。
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice yearly investigational pre-exposure prophylaxis (PrEP) injection. The ...
Lenacapavir has the potential to transform HIV care and prevention, but only if access is broadened, according to Jose Abrigo ...
It’s all the more tragic because HIV drugs can keep people from catching the virus, and prevent those living with the virus from passing it on. If everyone who needed these drugs could access them, ...
The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes ...
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
so that we can ensure a rapid transition to these voluntary license partners after lenacapavir for PrEP is approved.” Administered via subcutaneous injection every six months, the drug provides ...
这5,300多名受试者按照2:2:1的比例随机分配接受Lenacapavir、Descovy和Truvada用于HIV暴露前预防(PrEP)。Lenacapavir是一款衣壳抑制剂,每半年一针,通过 ...